Adalimumab Monoclonal Antibody from China
Adalimumab (Humira) is a fully human monoclonal antibody against TNF-alpha, treating autoimmune diseases like rheumatoid arthritis. It is imported as unmixed bulk under HTS 3002.13.0010, meeting the definition of immunological products directly regulating immune processes via biotech-derived proteins. Not in retail forms or measured doses.
Duty Rate — China → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Submit Form FDA 2877 for biologics and ensure biosimilar status if applicable for abbreviated pathways
• Monitor for stability data in import declarations to confirm non-degraded bulk product